George King Bio-Medical

What George King Bio-Medical does

George King Bio-Medical, Inc. is a privately held in vitro diagnostics manufacturer founded in 1973 by George J. King and headquartered in Overland Park, Kansas, specializing in frozen human plasma products for clinical coagulation and hemostasis diagnostics. The portfolio is organized into three main product lines — Coagulation Control Plasmas (Pooled Normal Plasma, FACT, B-FACT, A-FACT, Heparin Control, Single Donor Normal), Congenital Factor Deficient Plasmas (Factors V, VII, VIII, IX, X, XI, XII, XIII), and Specialty Control Plasmas (Positive Lupus Anticoagulant, Coumadin, Factor VIII with Inhibitor, Prekallikrein, von Willebrand Types 1, 2B, and 3) — supplemented by two convenience kits (CORE Kit and SysCOR 40 Control Kit). Products are sourced from carefully screened donors, including patients with congenital bleeding disorders, and are manufactured without buffers or preservatives so they closely resemble patient plasma; each lot ships with a Certificate of Analysis certifying assigned assay values.

The business sells to clinical laboratories and diagnostic facilities worldwide — primary customers are coagulation and thrombosis testing labs, with a secondary segment of research institutions and pharmaceutical companies requiring plasma for diagnostic reagent development and validation studies. Revenue is generated through direct unit-based sales of frozen plasma products on a quote-based, order-by-need model (no prepackaged minimums), with no disclosed pricing tiers. Domestically, orders are taken via phone, email, fax, and online quote requests by customer service representatives in the United States; internationally, distribution is handled through exclusive regional distributors — Cosmo Bio Co., LTD. in Japan and Szabo Scandic HandelsgmbH & Co KG covering nine European countries.

The company operates under an ISO 13485:2016-certified Quality Management System with FDA-licensed specialty source plasma facilities, and most products carry FDA Preamendment Status that predates the 1976 Medical Device Amendments. As of October 16, 2025, George King Bio-Medical operates as a subsidiary of Precision BioLogic Inc., a strategic acquirer with a complementary hemostasis diagnostics portfolio that includes Affinity Biologicals.

Name

George King Bio-Medical

Legal name

George King Bio-Medical, Inc.

Website

https://www.kingbiomed.com

Company type

Private

Founded year

1973

Operating status

Acquired

Headcount range

11–50 employees

Short description

George King Bio-Medical is a 1973-founded in vitro diagnostics manufacturer that produces frozen human plasma control and factor-deficient products used by clinical laboratories worldwide for coagulation and hemostasis testing. Following its October 2025 acquisition by Precision BioLogic, it operates as a subsidiary in a broader hemostasis diagnostics platform.

Ownership category

akta.pro rank

Headquarters

HQ city

Overland Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Plasma Products Sales: Sale of frozen human plasma products for clinical laboratory diagnostics. Products include control plasmas, factor deficient plasmas, specialty control plasmas, and diagnostic kits. Order-based model with no prepackaged amounts - customers order what they need.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

George King Bio-Medical manufactures and distributes frozen human plasma products for clinical coagulation and hemostasis diagnostics. Its portfolio includes coagulation control plasmas, congenital factor deficient plasmas, specialty control plasmas (lupus anticoagulant, Coumadin, von Willebrand, inhibitors), and diagnostic convenience kits. All products are sourced from carefully screened donors, including patients with congenital bleeding disorders, and contain no buffers or preservatives, making them most similar to patient plasma.

Product overview

George King Bio-Medical is a specialized provider of hemostasis diagnostic products focused on frozen human plasmas for clinical coagulation testing. The company's portfolio consists of three main product lines: Coagulation Control Plasmas (including Pooled Normal Plasma, FACT, B-FACT, A-FACT, Heparin Control Plasma, and Single Donor Normal Plasma), Factor Deficient Plasmas (congenital deficiencies of Factors V, VII, VIII, IX, X, XI, XII, and XIII), and Specialty Control Plasmas (including Positive Lupus Anticoagulant, Coumadin, Factor VIII with Inhibitor, Prekallikrein Deficient, and von Willebrand Types 1, 2B, and 3). Additionally, the company offers two convenience Kits: the CORE Kit for normal range evaluation and the SysCOR 40 Control Kit for instrument correlation. All products are frozen human plasmas with no buffers or preservatives, sourced from carefully screened donors including those with specific bleeding disorders. The company was acquired by Precision BioLogic in October 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Pooled Normal Plasma

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Precision BioLogic Inc.coreStrategic or Co-development Partner · 16 October 2025Strategic acquisition completed October 16, 2025. Precision BioLogic, a leading developer of hemostasis diagnostic products, acquired George King Bio-Medical to strengthen their position in diagnosing bleeding disorders and expand product offerings. Both organizations share similar purpose of helping individuals affected by bleeding disorders and will continue focusing on customers while developing longer term strategic plans under Precision BioLogic umbrella.
• Cosmo Bio Co., LTD.coreChannel Partner/ Reseller/ DistributorExclusive distributor for Japan. Located at Toyo-Ekimae Building, 2-20, Toyo 2-Chome, Koto-ku, Tokyo, Japan 135-0016. Handles distribution of all George King Bio-Medical products in Japan market.
• Szabo Scandic HandelsgmbH & Co KGcoreChannel Partner/ Reseller/ DistributorEuropean distributor covering Austria, Germany, France, Spain, Italy, Czech Republic, Netherlands, Belgium, and Luxembourg. Located at Quellenstraße 110, A-1100 Wien, Austria.
• Affinity BiologicalsminorStrategic or Co-development PartnerRelated company under Precision BioLogic. Precision BioLogic acquired Affinity Biologicals in November 2018 to expand clinical and research offerings with coagulation-related antibodies.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Diagnostica Stago: Global leader in hemostasis diagnostics with a broad portfolio of coagulation analyzers and reagents; competes with George King's specialty control products as part of a larger instrument-and-reagent platform.
• Werfen (Instrumentation Laboratory / IL): Hemostasis-focused diagnostic manufacturer (HemosIL, ACL series); sells clotting controls and deficient plasmas comparable to George King's product line as part of a broader instrument platform.
• Siemens Healthineers (Hemostasis): Broad incumbent in clinical hemostasis testing through its former DHS/Dimension lines; competes for coagulation control spending in hospital and reference labs.
• Sysmex: Major in vitro diagnostics company with a dedicated hemostasis business (formerly Siemens Healthineers' hemostasis); its instrument-tied controls and reagents compete for the same clinical lab wallets.

Direct peers

• Precision BioLogic: Parent company and direct peer — small specialty developer of hemostasis diagnostic products (including cryocheck controls); George King's product line is now complementary within Precision BioLogic's hemostasis portfolio.
• Helena Laboratories: Specialty manufacturer of hemostasis and hematology reagents and controls; comparable size and niche focus to George King in coagulation/thrombosis diagnostic consumables.
• Haematologic Technologies: Specialty provider of purified coagulation proteins and factor-deficient plasmas for research and clinical diagnostics; directly comparable offering in the factor-deficient substrate plasma segment.
• Affinity Biologicals: Coagulation-related antibody manufacturer acquired by Precision BioLogic in 2018; directly comparable as a small specialty hemostasis research/diagnostic reagent maker now operating as George King's sister company under Precision BioLogic.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/GKBioMed
• LinkedInlinkedin.com/company/george-king-bio-medical-inc.
• Xx.com/GKBioMed

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about George King Bio-Medical